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ABSTRACT 
Selective Inhibition of Insulin Growth-like Factor Receptor (IGFR) on Brain Endothelial Cells 
(BMECs) using Adeno-associated Virus (AAV) Serotype 9 
Jessica Lee 
Department of Veterinary Medicine and Biomedical Sciences 
Texas A&M University 
Research Advisor: Dr. Farida Sohrabji   
Department of Neuroscience and Experimental Therapeutics 
Texas A&M University 
Research Advisor: Dr. Shameena Bake 
Department of Neuroscience and Experimental Therapeutics 
Texas A&M University 
Ischemic stroke is the 5th leading cause of death within the U.S. and a major cause of 
long-term disability, especially in older females in comparison to men and younger women. This 
phenomenon is associated with a decrease in several steroid hormones including estrogen and 
the peptide hormone insulin growth-like factor (IGF)-1.1 In animal models, age-related loss of 
IGF-1 is associated with an increase in BBB permeability and worse stroke outcomes, including 
larger infarct volumes, greater sensory motor impairment, and increased neuroinflammation. 
Exogenous treatments of IGF-1 is shown to decrease BBB permeability and reduce brain infarct 
volume in middle-age female rats.8  Two main components of the BBB are astrocytes and brain 
microvessel endothelial cells (BMECs). Our recent studies demonstrated that targeted increases 
in IGF-1 expression in astrocytes  through AAV-mediated gene transfer improves stroke 
outcomes in middle-age rats. 10 These findings suggest that secreted astrocytic IGF-1 may act on 
endothelial cells to maintain the integrity of the blood brain barrier. To test this hypothesis, we 
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propose to block IGF-1 receptors (IGFR) in BMECs of young female rats that still produce 
normal amounts of IGF-1. By successfully doing so, we would then be able to understand the 
significance of IGF-1 signaling on stroke outcomes as it interacts with BMECs. Adeno-
associated virus (AAV) serotype 9, packaged with IGF1R shRNA and a mCherry reporter gene, 
was used to suppress the receptor. Mature adult female rats (5mo old) were injected with the 
control and siRNA containing AAV-9 vector. Integration of viral contents was assessed by 
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Age and Stroke Severity  
Stroke is more prevalent and has more severe impairment in older females after 
menopause.  Initially, this was attributed to the decrease in ovarian steroids such as estrogen, 
which is seen at menopause, and supported by preclinical studies showing that estrogen 
replacement decrease stroke infarct volume in younger females. However, in middle aged 
females, estrogen replacement has the opposite effect as evidenced by increased infarct volume 
and behavioral impairment in animal studies and in increased stroke occurrence in 
postmenopausal women.1 These results led our laboratory to investigate other molecules that 
may affect stroke outcomes.  
Functions of IGF-1 in the Brain  
Insulin growth-like factor (IGF)-1 is a polypeptide composed of 70 amino acids, which 
play many roles in growth and development. A majority of  IGF-1 is produced in the liver and 
circulates the body. Some amount of IGF-1 eventually gets transported across the BBB; 
however, brain cells such as astrocytes, neurons and microglia may also synthesize  IGF-1.2 IGF-
1 has similar insulin-like functions within the brain by promoting anabolic activity, which results 
in an overall increase of neuronal survival. IGF-1 promotes glucose utilization with the help of 
phosphatidylinositol 3- kinase (PI3K).3 Studies have also shown that IGF-1 contributes to 
neuroprotection from oxidative stress by activating signals that promote neuron protection.4  IGF-
1 contributes to maintaining overall brain integrity after stroke, such that a decrease in IGF-1 is 
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associated with worse stroke outcomes, while exogenous treatments of IGF-1 improves stroke 
recovery in males and middle aged females 1. 
Blood Brain Barrier  
Recent studies from this laboratory  have investigated the effects of IGF-1 on the blood 
brain barrier (BBB) and overall stroke outcomes. The principal cell type of the BBB is BMECs, 
and this structure creates an entryway for the transport of oxygen and nutrients from the blood 
circulation. Physicially, the BBB also serves as a protective barrier that maintains brain 
homeostasis by preventing pathogens and cytotoxic proteins from entering the brain.5   After 
stroke the BBB becomes more permeable and results in greater brain exposure to toxic products.  
Limiting permeability of the BBB is thought to help protect the brain during the occurrence of a 
stroke.6   Studies from our lab showed that post-stroke IGF-1 treatment targets proteins related to 
the PI3K-Akt pathway and  extracellular matrix proteins, both of which suggested that IGF-1 
may target  BBB function. 6 
Blood Brain Barrier Composition  
Two major components of that make up the BBB are astrocytes and endothelial 
cells.7   Astrocytes play a major role in repair after ischemic injury. With age, the neuroprotective 
capacity of astrocytes decreases.8,9  Specifically, aging astrocytes produce less IGF-1, which is 
associated with a poor stroke recovery. Our previous studies using adenovirus mediated delivery 
of the open reading frame of the human IGF-1gene (packaged in rAAV serotype 5), under a glial 
specific promoter (GFAP),  increased hrIGF-1 in astrocytes in the middle-aged brain  and  
resulted in better post-stroke outcomes in this age group. 10 .  In parallel,  our tissue culture 
studies showed that IGF-1 treatment to BMEC increases barrier properties in these cells.  Thus 
we propose that IGF-1 secreted by astrocytes, in vivo, may act on IGF-1 receptors (IGFR) on 
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endothelial cell of the BBB to reduce stroke injury. Astrocytes grown in contact with BMECs 
result with a tighter endothelium, which leads to an increased electrical resistance and overall 
protection.11   Furthermore, the IGF-1 receptor is reported to maintain normal brain function by 
interacting with glucose transporter 1 (GLUT1), regulating transport of glucose in the brain.12.  
Adeno-associated Virus Construct  
Adeno-associated virus (AAV) vectors are a commonly-used gene delivery tool for 
animal models. These replication-deficient vectors are used for their ability to localize in specific 
tissues, depending on the serotype, without eliciting a harmful immune response.11 The most 
recent  study from this laboratory used  AAV-5 vector to successfully transfect the IGF-1 gene in 
astrocytes.10 In this study, we will use AAV serotype 9 to target endothelial cells and silence the 


















Mature adult (5-6 months old) Sprague-Dawley female rats were purchased from Envigo 
Laboratories, Indiana and maintained at 12 hour light-dark cycles in the animal care facility at 
the MREB. All procedures were conducted in accordance with National Institute of Health 
guidelines on animal welfare and approved by the institutional committee on animal care. 
AAV Mediated Suppression of IGFR-1  
Adeno-associated viral vector  (serotype,-9) was used to silence IGFR-1 expression in  
brain microvessel endothelial cells  in the cortex and striatum.  This viral vector can establish 
latent infection and recombine genetic components into the DNA of specific cells of the body.  
Viral contents take at least 6 weeks to fully integrate. As shown in Fig 1, the viral vector was 
packaged with or without the IGF-1 receptor siRNA downstream of an endothelial specific 
promoter (PgP), and a mCherry fluorescent reporter gene. Once transfected, the virus integrate in 
brain cells and the siRNA results in  silencing of  IGF-1 receptor gene only in BMECs. The 




Fig. 1. Schematic representation of AAV9-shRNA-IGF1R construct (top) and control 




Stereotaxic Injections  
Rats were anesthetized using a combination of Xylazine and Ketamine based on their 
body weight (13 mg Xylazine/kg, 87 mg Ketamine/kg). Rats were then placed on a heating pad 
to maintain normal body temperature of 37oC. In preparation for surgery, the animals head was 
shaved and cleaned with alcohol wipes. The rats were placed in a stereotaxic instrument, and two 
small holes were drilled into their skulls at specific coordinates relative to the bregma, 
corresponding to the striatum and the cortex respectively. The coordinates for the striatum were 
+0.9mm anterior posterior, -3.6 mm medial lateral, and -6.5 mm depth. For the cortex, the 
coordinates were +0.9 mm anterior posterior, -5.5 mm medial lateral, and -6.0 depth. The control 
or siRNA containing AAV9 construct was injected injected at a flow rate of 0.5 ul every 30 
seconds for 3 min. The concentration of AAV9 injected was 2.5 x 1012 viral particles (VP)/mL 
(Signagen, MD). After injection, the scalp was sutured and the rats were returned to their  cages 
and placed under a warm lamp. Amimals were carefully monitored until they regained 
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consciousness. The rats were then returned to the vivarium and maintained for 6 weeks allowing 
for recovery and integration of the viral contents. 
Brain Extractions for Sectioning  
Rats were anesthetized using a combination of Xylazine and Ketamine (13 mg 
Xylazine/kg, 87 mg Ketamine/kg), and perfused transcardially with sterile phosphate buffered 
saline (dPBS) followed by 4% paraformaldehyde. Brain were then removed from the skull and 
placed in PBS at 4 oC overnight. The brains were then transferred to a 15% sucrose solution 
overnight and later embedded in cryomedia and cryosectioned. Sections (30 um thickness) were 
placed on glass slides in preparation for histological analysis.  
Microvessel Extraction  
A parallel set of animals were deeply anesthetized (13 mg Xylazine/kg, 87 mg 
Ketamine/kg) and their brains were rapidly removed from the skull. The overlying meninges 
were removed and the cortex and striatum were dissected and harvested for microvessels. 
Briefly, tissues were homogenized in sterile PBS in a Dounce homogenizer with loosely fitting 
pestle of 6-7 gentle strokes. The homogenates were spun briefly at 720 g for 5 min at 4oC. The 
resulting pellet was suspended in PBS and layered over 18% dextran, spun at 2500 rpm for 30 
min. The pellet was suspended again in PBS and then filtered through a 150 um filter. The 
filtrate were passed through a 70 um filter. The vessels were recovered from the filter by 
squirting PBS. The suspension of vessels were spun again at 1000 rpm for 5 minutes and the 
final pellet suspended in PBS, and dropped onto coated/charged slides and air dried.  For RNA 





Histochemical staining and immunohistochemistry was performed on brain sections and 
microvessels. (1) Lectin (1:500, vector laboratories,CA) conjugated to a green fluorescent 
marker was used  to detect endothelial cells. (2) Antibodies to IGFR were used to detect IGFR by 
immunostaining (1:200 primary; 1:500 secondary), (3) Antibodies to Glial Fibrillary Acidic 
Protein (GFAP) (1:200 primary; 1:500 secondary) was used to identify astrocytes.  For IGFR and 
GFAP immunohistochemistry, a negative control was also prepared that received the secondary 
antibody (1:500) only. For all staining protocols a nuclear counterstain was applied prior to 
coverslipping the slides. Images were taken with a Q-colors 3 microscope.  
RNA Preparation  
RNA Extractions  
Brain microvessels previously stored in -80 deg. C were allowed to thaw on ice. A 
Qiagen miRNAeasy Mini Kit (stored at room temperature) was used to extract RNA from 
microvessels. QIAzol Lysis reagent was added to 1.5 mL tubes containing microvessels, 
sonicated for ~20 seconds, and incubated at room temperature for 5 minutes. Chloroform was 
added to the homogenized cells, shaken, and centrifuged at 12,000 x g for 15 minutes. The upper 
aqueous phase was transferred to another collection tube and mixed with 100% ethanol. This 
solution was then added to a column-collection tube and centrifuged at 8000 x g for 15 sec. 
(room temperature).  This step was repeated after addition of RWT and RPE buffer respectively. 
RPE buffer was added again and centrifuged for 2 minutes (8000 x g).  Lastly, RNAase-free 
water was added to the column and centrifuged for 1 minute (8000 x g); the flow through 
contained extracted RNA and was stored at -20 deg. C. Nucleic acid concentration was 
quantified using the Nanodrop 2000 spectrophotometer.  
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Complementary (c)DNA Synthesis 
cDNA synthesis from microvessel RNA was performed using the qScript kit following 
manufacture’s instructions. Briefly,  equal volume  of  RNA template (100ng) was used in the 
reaction mix along with  RNAase free water. Tubes with reaction mix and samples were placed 
in a thermocycler programmed for incubation for 5 minutes at 25 deg. C, 30 minutes at 42 deg. 
C, 5 minutes at 85 deg. C,. The synthesized cDNA was stored in -20 deg. C until further use. 
Quantitative PCR (qPCR) 
qPCR was performed on the cDNA to confirm the suppression of the IGF-1 receptor gene 
expression in BMECs. Synthesized cDNA was diluted (1:3) with RNAase-free water. Samples 
were mixed with PerfeCTa SYBR Green Fastmix (1x), and primers for 18 S (housekeeping 
gene) or rat IGF1R primer (Table 1). Each primer mix contained the forward and reverse primer. 
cDNA and reagents were pipetted carefully into a PCR plate, sealed and spun, and amplified in a 
ViiA7 Real-time PCR system. Cycle threshold (𝐶!) values were calculated, and group differences 
were tested  using student’s t-test (significance was considered at p<0.05) 
Table 1: Forward and Reverse Primer Sequences for qPCR 
Gene Name Forward Primer Reverse Primer 
Rat IGF-1R CAATATCACAGACCCGGAAG ATGTCATCTGCTCCTTCTGC 
18S ATGGCCGTTCTTAGTTGGTG CGCTGAGCCAGTCAGTGTAG 
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Figure 2: Confirmation of the Viral Integration in BMECs. Brain sections stained with fluorescein 
conjugated lectin (green) showing endothelial cells on cross sections of blood vessels. The mCherry reporter 






Immunohistochemistry Analysis  
Brain Sections  
Brain microvessels were clearly detected by lectin staining in whole brain sections (Fig 
2).  In Figure 2, green fluorescence indicated lectin stained microvessels, while red fluorescence 
(due to the mCherry reporter) indicates the integration of the AAV-9 viral contents within these 
microvessels. These images provide evidence for co-localization of AAV9-mcherry in these brain 






Figure 3: Immunohistological Comparison of IGF-1 Receptor Expression in Brain Microvessels. BMECs 
were extracted and immunostained with an IGFR antibody labeled with  green fluorescence. The red color 
indicates mCherry reporter gene expression in these microvessels. The images were taken at 20X magnification.  
Note the colocation of IGFR in mCherry positive cells in the control microvessels, and the reduced IGFR (green) 
expression in mCherry positive cells in the vessels from the shRNA-IGF1R construct injected animals. 
 
Microvessels  
In order to assess the impact of rAAV9 on IGFR expression, brain microvessels were 
extracted and probed for the IGF-1 receptor using an immunostaining staining protocol. As 
shown in Figure 3, colocalization of mCherry (rAAV; red fluorescence) and IGFR 
immunoreactivity (green) resulted in the presence of yellow-orange cells (indicated by arrows) in 
control microvessels. In contrast, there was little overlap in rAAV positive cells and IGFR label 
in microvessels from animals that received the siRNA construct, consistent with the possibility 









Fig. 4. Comparison of IGF-1 Receptor Gene Expression. qPCR analysis was perfomed and the threshold 
cycles (𝐶!) were quantified for samples receiving the IGF1R Rat Primer and 18S Housekeeping Gene 
Primer (standard). The threshold cycle was normalized by calculating ∆𝐶! = 𝐶!(!"#!!) − 𝐶! (!"!) shown in 
the y-axis. There were two groups compared: 1) AAV9-IGF1R –shRNA and 2) AAV-9-control vector . The 
left and right hemispheres were also compared, left being the non-injected site (control) and right being the 
injected site. Our sample size was 2 and had standard error values = 0.148 (Right-siRNA), 0.043 (Right-
control), 0.088 (Left-siRNA), 0.327 (Left-control). Note that the threshold cycle has an inverse relationship; 


























Threshold cycles (𝐶!) were quantified for IGFR amplicons and normalized to 18S for the 
injected and non-injected hemisphere of control and AAV9-IGF1R-shRNA injected animals. 
The AAV9-IGF1R-shRNA injected group had a higher ∆𝐶! value, which indicates a lower IGFR 
gene expression, in comparison to the control group, and statisitical analyses indicated a trend 
(p< 0.075) towards a significant difference.  Interestingly, no such trend was detected on the non-
injected side, where the control and AAV9-IGF1R-shRNA animals displayed similar levels of 
IGFR gene expression (p<0.825).  One possibility for the statistical ‘trend’ may be due to the 
































The main objective of this research project was to develop a successful experimental 
strategy to suppress IGF-1 receptors in brain endothelial cells. Images taken from the 
immunohistochemistry analysis on the brain sections show that rAAV9 is localized to cells in 
lectin stained vessels, which confirms the integration of the viral contents within brain 
microvessel endothelial cells.  In order to test suppression of the IGF-1 receptor, microvessels 
were extracted and stained for IGFR. Images taken from the microvessels showed inhibition of 
the IGF-1 receptor for animals injected with the shRNA-IGF-1R construct in comparison to the 
control vector group. A qPCR analysis on microvessel RNA showed a trend toward down 
regulation of the IGFR gene in animals injected with the AAV9-IGF1R-shRNA construct. These 
pilot findings will be studied in additional animals to confirm the utility of viral mediated 
suppression of IGFR in BMECs. If this approach is successful, future studies will determine how 
endothelial IGFR impacts stroke outcome in adult female rats. 
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